Boston Scientific Corporation (NYSE:BSX) saw unusually large options trading activity on Tuesday. Stock investors acquired 5,848 call options on the company. This is an increase of 1,042% compared to the typical daily volume of 512 call options.

Boston Scientific (NYSE:BSX) opened at $26.28 on Friday. Boston Scientific has a 12-month low of $19.67 and a 12-month high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The firm has a market cap of $36,238.64, a PE ratio of 21.63, a PEG ratio of 2.04 and a beta of 1.00.

Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, hitting the consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the company posted $0.27 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. sell-side analysts expect that Boston Scientific will post 1.25 earnings per share for the current year.

In other news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The shares were acquired at an average price of $0.45 per share, with a total value of $183,602.70. Also, EVP Timothy A. Pratt sold 11,061 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the sale, the executive vice president now directly owns 174,681 shares in the company, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders have sold 414,698 shares of company stock worth $12,013,153 over the last three months. 0.74% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC acquired a new position in shares of Boston Scientific in the third quarter worth about $138,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Boston Scientific in the third quarter worth approximately $139,000. Acrospire Investment Management LLC lifted its position in shares of Boston Scientific by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 3,100 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its position in shares of Boston Scientific by 14.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after purchasing an additional 720 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA purchased a new stake in shares of Boston Scientific in the second quarter worth approximately $191,000. Institutional investors own 90.55% of the company’s stock.

A number of analysts recently weighed in on the stock. SunTrust Banks set a $34.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a report on Tuesday, October 31st. Zacks Investment Research cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. BidaskClub cut shares of Boston Scientific from a “hold” rating to a “sell” rating in a research note on Saturday, August 26th. Oppenheimer reissued a “hold” rating on shares of Boston Scientific in a research note on Wednesday, August 9th. Finally, BMO Capital Markets reissued a “buy” rating and set a $31.00 target price on shares of Boston Scientific in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $30.67.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/01/boston-scientific-sees-unusually-high-options-volume-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.